Last reviewed · How we verify
KRX-0502
KRX-0502, marketed by Keryx Biopharmaceuticals, is a small molecule with a key composition patent expiring in 2028. The drug's mechanism of action involves interacting with specific biological targets to produce a therapeutic effect, though its primary indication and revenue figures are not specified. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | KRX-0502 |
|---|---|
| Also known as | ferric citrate |
| Sponsor | Keryx Biopharmaceuticals |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease (PHASE3)
- Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease (PHASE3)
- KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial) (PHASE4)
- A Pilot Study of KRX-0502 (Ferric Citrate, Administered Without Food, in Treating Iron-deficiency Anemia (PHASE2)
- KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD (PHASE3)
- Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis (PHASE2)
- A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) (PHASE2)
- A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KRX-0502 CI brief — competitive landscape report
- KRX-0502 updates RSS · CI watch RSS
- Keryx Biopharmaceuticals portfolio CI